Humira
E697096
Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Humira canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7930811 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Humira Context triple: [AbbVie, notableProduct, Humira]
-
A.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
B.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Humira Target entity description: Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
-
A.
Kevzara
Kevzara is a prescription monoclonal antibody medication (sarilumab) used to treat adults with moderate to severe rheumatoid arthritis by targeting the interleukin-6 (IL-6) receptor.
-
B.
Remicade
Remicade is a widely used monoclonal antibody biologic (infliximab) prescribed to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
C.
Stelara
Stelara is a prescription biologic medication (ustekinumab) used to treat autoimmune conditions such as psoriasis, psoriatic arthritis, and Crohn’s disease by targeting specific immune system pathways.
-
D.
Rituxan
Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
-
E.
Actemra
Actemra is a prescription biologic medication (tocilizumab) used to treat inflammatory conditions such as rheumatoid arthritis by inhibiting the interleukin-6 (IL-6) receptor.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
biologic medication
ⓘ
monoclonal antibody ⓘ tumor necrosis factor inhibitor ⓘ |
| approvalBy |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvalYear | 2002 ⓘ |
| bindsTo |
membrane-bound TNF-alpha
ⓘ
soluble TNF-alpha ⓘ |
| blackBoxWarning |
malignancy
ⓘ
serious infections ⓘ |
| commonAdverseEffect |
headache
ⓘ
injection site reaction ⓘ upper respiratory tract infection ⓘ |
| contraindication |
active serious infection
ⓘ
moderate to severe heart failure ⓘ |
| developer | AbbVie NERFINISHED ⓘ |
| hasATCCode | L04AB04 ⓘ |
| hasDosageForm |
pre-filled pen
ⓘ
pre-filled syringe ⓘ |
| hasDrugClass |
TNF-alpha inhibitor
ⓘ
immunosuppressive agent ⓘ |
| hasGenericName | adalimumab ⓘ |
| hasINN | adalimumab ⓘ |
| hasRouteOfAdministration | subcutaneous injection ⓘ |
| indication |
Crohn's disease
ⓘ
ankylosing spondylitis ⓘ hidradenitis suppurativa ⓘ juvenile idiopathic arthritis ⓘ non-infectious intermediate uveitis ⓘ non-infectious panuveitis ⓘ non-infectious posterior uveitis ⓘ plaque psoriasis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ uveitis ⓘ |
| isAdministeredBy | patient self-injection ⓘ |
| isBiologic | true ⓘ |
| isBiosimilarAvailable | true ⓘ |
| mechanismOfAction | binds to TNF-alpha and blocks its interaction with TNF receptors ⓘ |
| molecularType | recombinant human IgG1 monoclonal antibody ⓘ |
| originalDeveloper | Abbott Laboratories NERFINISHED ⓘ |
| pregnancyCategoryUS | B ⓘ |
| reduces | inflammatory response mediated by TNF-alpha ⓘ |
| requiresMonitoring |
hepatitis B reactivation
ⓘ
signs of infection ⓘ tuberculosis ⓘ |
| targets | tumor necrosis factor alpha NERFINISHED ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Humira Description of subject: Humira is a widely used biologic medication (adalimumab) that treats various autoimmune diseases such as rheumatoid arthritis, psoriasis, and Crohn’s disease by inhibiting tumor necrosis factor (TNF).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.